contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


members-of-lumitos-board-and-management-team-intend-to-exercise-warrants-of-series-to6

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Lumito specializes in medical technology for digital pathology. The company strives to improve tissue diagnostics with its patented technology based on upconverted nanoparticles. The company plans to initially launch its first product for research laboratories. The company was formed in 2010 as a spinoff from a research group at Lund University's Department of Atomic Physics and Laser Center. Lumito has its headquarters in Lund.

Lumito

Members of the board and management that hold warrants of series TO6 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand.The board...

<div class="mfn-preamble"><p><strong>Members of the board and management that hold warrants of series TO6 Lumito AB (publ) ("Lumito" or the "Company") intend to exercise 575,512 warrants to a value of SEK 224 thousand.</strong></p></div><div class="mfn-body"><p>The board and management team intends to exercise warrants, directly or via companies, according to the following:</p><ul><li>Kerstin Jakobsson (Chair of the Board) – 75,000 warrants of series TO6, corresponding to approximately SEK 29 thousand</li></ul><ul><li>Marcus Åström (Board Member) – 400,000 warrants of series TO6, corresponding to approximately SEK 156 thousand</li></ul><ul><li>Mattias Lundin (Board Member) – 33,332 warrants of series TO6, corresponding to approximately SEK 13 thousand</li></ul><ul><li>Sanna Wallenborg (CEO) – 67,180 warrants of series TO6, corresponding to approximately SEK 26 thousand</li></ul><p>The exercise period for warrants of series TO6 commenced on November 4, 2024, and continues to and including November 15, 2024. Complete terms for the warrants are available on the Company’s website, <a rel="noopener" href="https://www.lumito.se/en/">www.lumito.se</a>.</p><p><strong>Advisers</strong><br>Mangold Fondkommission AB is financial adviser and Advokatfirman Lindahl KB is legal advisor to Lumito in connection with the exercise of the warrants of series TO6.</p></div><div class="mfn-footer mfn-contacts mfn-1c72a901341e"><p><strong class="mfn-heading-1">For further information, please contact:</strong></p><hr><p>Sanna Wallenborg, CEO Lumito<br>E-mail:&nbsp;<a rel="noopener" href="mailto:sw@lumito.se">sw@lumito.se</a><br>Ph: +4670-870 01 68</p></div><div class="mfn-footer mfn-about mfn-a888ce5bf1d4"><p><strong class="mfn-heading-1">About Lumito</strong></p><hr><p><strong>Lumito</strong>&nbsp;specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The&nbsp;company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre.&nbsp;<a rel="noopener" href="http://www.lumito.se/en">www.lumito.se/en</a></p><p>The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/2069b15e-0acc-47d4-a343-c9172e3e93dc/members-of-lumitos-board-and-management-team-intend-to-exercise-warrants-of-series-to6.pdf" class="mfn-generated mfn-primary">Members of Lumitos board and management team intend to exercise warrants of series TO6</a></p></div>

Members of Lumitos board and management team intend to exercise warrants of series TO6

Stay up to date with our newsletter